Cambridge Trust Co. reduced its holdings in shares of Danaher Corporation (NYSE:DHR) by 0.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 147,983 shares of the conglomerate’s stock after selling 1,268 shares during the period. Cambridge Trust Co.’s holdings in Danaher were worth $12,694,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in DHR. GQG Partners LLC acquired a new stake in Danaher during the 2nd quarter worth $101,000. Proficio Capital Partners LLC boosted its stake in Danaher by 92.3% during the 1st quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock worth $105,000 after purchasing an additional 598 shares during the period. Monetary Management Group Inc. raised its position in Danaher by 10.7% during the 2nd quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after buying an additional 150 shares during the last quarter. Acrospire Investment Management LLC raised its position in Danaher by 185.5% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after buying an additional 1,100 shares during the last quarter. Finally, Motco raised its position in Danaher by 8.8% during the 2nd quarter. Motco now owns 2,011 shares of the conglomerate’s stock worth $170,000 after buying an additional 163 shares during the last quarter. 76.32% of the stock is currently owned by institutional investors.
Danaher Corporation (DHR) traded down $0.21 on Wednesday, hitting $92.53. 2,038,382 shares of the stock were exchanged, compared to its average volume of 2,630,318. The stock has a market capitalization of $64,566.07, a price-to-earnings ratio of 23.86, a P/E/G ratio of 2.21 and a beta of 1.02. Danaher Corporation has a 12 month low of $76.27 and a 12 month high of $94.82. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00.
Danaher (NYSE:DHR) last issued its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.05. The business had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The business’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.87 earnings per share. analysts forecast that Danaher Corporation will post 3.99 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be issued a dividend of $0.14 per share. The ex-dividend date is Thursday, December 28th. This represents a $0.56 annualized dividend and a yield of 0.61%. Danaher’s payout ratio is presently 16.52%.
In other Danaher news, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total value of $11,671,620.96. Following the completion of the transaction, the chief executive officer now directly owns 271,737 shares in the company, valued at $25,173,715.68. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Donald J. Ehrlich sold 10,578 shares of the firm’s stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total value of $960,693.96. Following the completion of the transaction, the director now owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The disclosure for this sale can be found here. Insiders sold a total of 273,810 shares of company stock worth $25,218,813 in the last quarter. 12.20% of the stock is owned by corporate insiders.
DHR has been the subject of a number of analyst reports. Morgan Stanley upped their price objective on shares of Danaher from $95.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, October 20th. Credit Suisse Group increased their price target on shares of Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Zacks Investment Research upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a report on Thursday, October 5th. Goldman Sachs Group restated a “neutral” rating and set a $83.00 target price on shares of Danaher in a report on Tuesday, September 26th. Finally, Robert W. Baird raised their target price on shares of Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Danaher has an average rating of “Buy” and an average price target of $93.31.
WARNING: “Danaher Corporation (DHR) Shares Sold by Cambridge Trust Co.” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/12/07/cambridge-trust-co-sells-1268-shares-of-danaher-corporation-dhr.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.